Golden Biotechnology (TPEX:4132) - Share price, News & Analysis

4132 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

4132 Stock Overview

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore.

Risk Analysis

Earnings have declined by 9.2% per year over past 5 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have meaningful revenue (NT$82M)

Golden Biotechnology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Golden Biotechnology
Historical stock prices
Current Share Price	NT$152.00
52 Week High	NT$335.00
52 Week Low	NT$50.50
Beta	0.28
1 Month Change	-10.85%
3 Month Change	-11.88%
1 Year Change	160.27%
3 Year Change	191.41%
5 Year Change	210.90%
Change since IPO	310.81%

Recent News & Updates

Mar 18

Does Golden Biotechnology's (GTSM:4132) Share Price Gain of 86% Match Its Business Performance?

A diverse portfolio of stocks will always have winners and losers. But the goal is to pick stocks that do better than...

Shareholder Returns

	4132	TW Biotechs	TW Market
7D	7.4%	-0.9%	2.0%
1Y	160.3%	7.8%	-0.2%

Return vs Industry: 4132 exceeded the TW Biotechs industry which returned 7.8% over the past year.

Return vs Market: 4132 exceeded the TW Market which returned -0.2% over the past year.

Price Volatility

Is 4132's price volatile compared to industry and market?
4132 volatility
4132 Average Weekly Movement	7.5%
Biotechs Industry Average Movement	5.2%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.2%
10% least volatile stocks in TW Market	2.2%

Stable Share Price: 4132 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 4132's weekly volatility has decreased from 17% to 7% over the past year, but is still higher than 75% of TW stocks.

About the Company

Founded	Employees	CEO	Website
2002	122	Li Yu Wu	https://www.goldenbiotech.com.tw

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, as well as hypercholesterolemia and hyperlipidemia.

Golden Biotechnology Fundamentals Summary

How do Golden Biotechnology's earnings and revenue compare to its market cap?
4132 fundamental statistics
Market Cap	NT$21.62b
Earnings (TTM)	-NT$443.84m
Revenue (TTM)	NT$81.77m

264.4x

P/S Ratio

-48.7x

P/E Ratio

Is 4132 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
4132 income statement (TTM)
Revenue	NT$81.77m
Cost of Revenue	NT$69.08m
Gross Profit	NT$12.69m
Other Expenses	NT$456.52m
Earnings	-NT$443.84m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-3.12
Gross Margin	15.51%
Net Profit Margin	-542.80%
Debt/Equity Ratio	26.2%

How did 4132 perform over the long term?

See historical performance and comparison

Valuation

Is Golden Biotechnology undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

20.87x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4132's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4132's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 4132 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 4132 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4132's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 4132 is overvalued based on its PB Ratio (20.9x) compared to the TW Biotechs industry average (3.8x).

Future Growth

How is Golden Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

143.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Golden Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Golden Biotechnology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-9.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4132 is currently unprofitable.

Growing Profit Margin: 4132 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 4132 is unprofitable, and losses have increased over the past 5 years at a rate of 9.2% per year.

Accelerating Growth: Unable to compare 4132's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4132 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).

Return on Equity

High ROE: 4132 has a negative Return on Equity (-42.85%), as it is currently unprofitable.

Financial Health

How is Golden Biotechnology's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 4132's short term assets (NT$1.1B) exceed its short term liabilities (NT$411.3M).

Long Term Liabilities: 4132's short term assets (NT$1.1B) exceed its long term liabilities (NT$40.5M).

Debt to Equity History and Analysis

Debt Level: 4132 has more cash than its total debt.

Reducing Debt: 4132's debt to equity ratio has increased from 23.7% to 26.2% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4132 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4132 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 2.6% each year

Dividend

What is Golden Biotechnology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4132's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4132's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4132's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4132's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 4132 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Li Yu Wu

no data

Tenure

Li Yu Wu serves as President and Director of Golden Biotechnology Corp. and served as its Co-Chief Executive Officer.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.6%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/22 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31